A Review on Prevention and Eradication of Poliomyelitis

Abstract

Despite marked progress in world acute anterior poliomyelitis demolition, the threat of acute anterior poliomyelitis importation into the US remains; so, all youngsters should be protected against the sickness. The quality schedule for poliovirus immunisation remains four doses of inactivated vaccinum at 2, 4, and 6 through eighteen months and four through six years more matured. The minimum interval between doses one two and between doses 2 and three is 4 weeks, and also the minimum interval between doses three and four is vi months. The minimum age for dose one is vi weeks. Nominal age and intervals should be used once there's impending threat of exposure, such as travel to a part within which acute anterior poliomyelitis is endemic or epidemic. the ultimate dose in the inactivated vaccinum series ought to be administered at four through six years more matured, notwithstanding the previous variety of doses administered before the fourth birthday, and a minimum of six months since

Keywords

Poliomyelitis, Central Nervous System, Poliovirus, Vaccine, Post-Polio Syndrome

Introduction

Poliomyelitis is an irresistible illness brought about by the poliovirus; it is regularly called as polio or juvenile loss of motion. Poliomyelitis is created by [1-6] any of the three serotypes of poliovirus. Polio disease has two essential examples: a minor sickness which does not influence the focal sensory system (CNS) can be called failed poliomyelitis and a noteworthy ailment influencing the CNS, which can be crippled or non-paralytic. The vast majority of the populace who have ordinary insusceptible framework, a poliovirus contamination is asymptomatic. It's extremely uncommon that the contamination indicates minor manifestations; like [7,8] gastrointestinal unsettling influences (queasiness, stomach torment regurgitating, stoppage or looseness of the bowels) and flu like ailment; at some point upper respiratory tract disease like sore throat and fever can likewise show up.

There are just 1% of diseases in which infection enters the focal sensory system. The greater part of the influenced populace with CNS contribution experience non-paralytic aseptic [9,10] meningitis and experience compelling undeniable irritation, (back, guts), heaving, fever, laziness and crabbiness. Around one to five in 1000 cases create disabled sickness in which the muscle become feeble and ineffectively controlled, and after that at last goes to a phase of [11,12] complete loss of motion; this condition is known as intense limp loss of motion. Incapacitated poliomyelitis is delegated spinal, bulbar or bulbospinal relying upon the site of loss of motion. There are uncommon cases in which encephalitis, a contamination of the cerebrum tissue itself can happen yet it is normally confined to newborn children. Encephalitis is characterized [13,14] by changes in mental status, disarray, migraines, fever, and, less generally, seizures and spastic loss of motion.

Poliovirus is a profoundly infectious infection and is particular to people, causes polio. The infection as a rule enters the earth in the excrement of the person who is contaminated. For the most part ranges with poor sanitation are at more hazards to be contaminated by poliovirus as the infection effectively spreads from defecation into the water supply or by touch, into sustenance.

Furthermore, in light of the fact that polio is so infectious, direct contact with [15] an individual contaminated with the infection can bring about polio. People who convey the poliovirus can spread it by means of their dung for quite a long time, regardless of the fact that they have demonstrated no side effects themselves.

Once the virus [16-19] has entered an individual, it contaminates the cells of the throat and digestive tract. It assumes control over the host's cell hardware and starts to reproduce. The infection stays inside the digestion tracts, quickly isolating for a week and prior to spreading to different territories of the body. In the end, the infection moves into the circulation system where it can spread to the whole body.

Polio virus

Poliovirus is a human enterovirus that originates from the group of Picornaviridae which is the causative operator of poliomyelitis. The main normal hosts of poliovirus are people. The infection, notwithstanding, can spread to monkeys when it is straightforwardly vaccinated into the [20-23] central sensory system (CNS). The species specificity of this infection is represented by a particular cell surface atom that serves as the poliovirus receptor (PVR). Indeed, even the transgenic mice having the human poliovirus receptor (hPVR/CD155) quality show powerlessness to poliovirus disease, despite the fact that mice as a rule are not defenseless to poliovirus.

Structure

A poliovirion incorporates a solitary stranded RNA genome of positive extremity and a non-concealed capsid that contains 60 duplicates of each of 4 capsid proteins: VP1, VP2, VP3, and VP4. The three-dimensional structure has been expounded and the [24-28] study uncovered dejections called ""gorge"" on the virion surface, which have been appeared to be the potential connection destinations for Poliovirion. The genome of the poliovirus capacities as mRNA in the cytoplasm of contaminated cells. The infection specific [29-30] interpretation process starts with the passage of ribosomes into the inside ribosome section site (IRES) inside the 5' noncoding arrangement of the RNA and every single viral protein are deciphered as a substantial forerunner protein from a solitary open perusing outline that is co-translationally prepared into [30-33] useful viral proteins. Poliovirus is recognized into 3 stable serotypes (sorts 1, 2, and 3), and each serotype is potential to bring about poliomyelitis. In order to forestall or control poliomyelitis, weakened poliovirus strains of every one of the 3 serotypes (Sabin 1, Sabin 2, and Sabin 3) have been created and are used adequately as [34-36] oral polio immunizations (OPV). After the ingestion of oral polio antibody, these Sabin strains begin imitating to an adequately abnormal state in the human wholesome tract to evoke killing antibodies, in spite of the fact that the infection can possibly move into the circulatory system and repeat in the CNS.

Pathogenesis

In people, poliovirus [37-40] disease generally starts with oral utilization of the infection. After the infection enters orally, it begins duplicating in the wholesome mucosa and conceivably in the tonsils and Peyer's patches. The infection then moves into the circulatory system through the putative barrier(s) that harmful poliovirus strains cross more proficiently than weakened strains. The flowing infection attacks the CNS and begins duplicating in neurons, particularly engine neurons. The circulating [41,42] poliovirus can enter the CNS by two conceivable scattering courses. One is infection penetration through the blood-mind obstruction (BBB), and the other is infection transmission by means of fringe nerves. Because of neuronal demolition by lytic replication of the poliovirus, disabled poliomyelitis happens which is uncommon as it happens in under 1% of populace contaminated.

Types of Polio

There are three types of polio infections:

Sub-clinical

Roughly 95 percent of [43,44] polio cases are sub-clinical in which tolerant does not encounter any indications. This type of polio does not influence the focal sensory system (the cerebrum and spinal string).

Non-paralytic

This form influences the focal sensory system and patient experience just gentle side effects and does not bring about loss of motion.

Sore throat ,Fever, Back and neck torment ,Headache ,Vomiting ,Arm and leg solidness, Fatigue ,Muscle delicacy and fits ,Meningitis - a contamination of the layers encompassing the brain.

Paralytic

This is the rarest and [45,46] most incessant type of polio, which grows full or halfway loss of motion in the patient. Disabled polio influences just little measure of patients contaminated by the polio infection. In these cases, the infection enters engine neurons where it repeats and pulverizes the cells. These cells are ordinarily in the spinal rope, cerebrum stem, or engine cortex - a range of the mind critical in controlling developments.

Manifestations of incapacitated polio frequently begin comparatively to non-crippled polio; however later create to more genuine indications, for example: severe muscle torment and fits, lost muscle reflexes, Loose or floppy appendages that are regularly more terrible on one side of the body.

Post-Polio Syndrome

PPS is recognized by further debilitating of muscles [47-49] that were already influenced by the polio disease. PPS is a condition that influences polio survivors 10 to 40 years after recuperation from an underlying contamination; manifestations incorporate gradually dynamic muscle shortcoming and weakening, exhaustion. Joint torment and bone deformations are regular. PPS is for the most part not life-undermining. There is no known [50] cause or viable treatment for PPS.

The most generally acknowledged hypothesis of the system behind the turmoil is "neural exhaustion". An engine unit is a nerve cell (or neuron) and the muscle filaments it actuates. Poliovirus assaults specific neurons in the brainstem and the foremost horn cells of [51] the spinal line, for the most part bringing about the decimation of a considerable division of the engine neurons controlling skeletal muscles. With a specific end goal to make up for the loss of these neurons, the staying engine neurons grow new nerve terminals to the stranded muscle filaments. The outcome is some recuperation of development and the improvement of extended engine units.

The neural weariness hypothesis proposes that the [52] amplification of the engine neuron filaments places included metabolic anxiety the nerve cell body to sustain the extra strands. Following quite a while of utilization, this anxiety might be more than the neuron can deal with, prompting the progressive corruption of the grew strands and in the long run the neuron itself. This causes shortcoming in the muscle and loss of motion. In a few strands restoration [53-56] of nerve capacity can happen a second time, however after at some point nerve terminals breakdown and perpetual shortcoming happens. At the point when these neurons are no more ready to bear on growing, weakness happens because of the expanding metabolic interest of the sensory system. The ordinary maturing process additionally has some impact. There is a progressing denervation and reinnervation, however the reinnervation [57,58] process has a furthest point of confinement where the reinnervation is not ready to make up for the continuous denervation and loss of engine units happens. However the explanation for the unsettling influence of denervation-reinnervation balance is uncertain. As the age increments the vast majority confront a diminishing in the quantity of spinal engine neurons. As there is lost extensive measure of engine neurons in polio, further age-related loss of neurons may add to new muscle weakness.

Diagnosis of polio

Paralytic poliomyelitis might be clinically analyzed [59,60] in people encountering intense onset of limp loss of motion in one or more appendages with truant ligament reflexes in the influenced appendages that can't be attributed to another clear cause, and without tactile or subjective misfortune.

A feces test or a swab of the pharynx is taken for the recuperation of poliovirus to run analytic test for recognition of polio in lab. Antibodies to poliovirus [61-63] can be analytic, and are for the most part recognized in the blood of contaminated patients right on time over the span of disease. Investigation of the patient's cerebrospinal liquid (CSF), which is gathered by a lumbar cut ("spinal tap"), uncovers an expanded number of white platelets (basically lymphocytes) and a somewhat raised protein level. Location of infection in the CSF is symptomatic of crippled polio, however once in a while happens.

On the off chance that poliovirus is segregated from a patient [64,65] encountering intense flabby loss of motion, it is further tried through oligonucleotide mapping (hereditary fingerprinting), or all the more as of late by PCR intensification, to figure out if it is "wild sort" (that is, the infection experienced in nature) or "immunization sort" (got from a strain of poliovirus used to deliver polio antibody). It is imperative to decide the wellspring of the infection on the grounds that for each reported instance of immobile polio brought on by wild poliovirus, an expected 200 to 3,000 different infectious asymptomatic bearers exists.

Laboratory Testing

Viral Isolation

Poliovirus might be recouped from the stool, is less likely [66] recuperated from the pharynx, and just once in a while recuperated from cerebrospinal liquid (CSF) or blood. In the event that poliovirus is disconnected from a man with intense limp loss of motion, it must be tried further, utilizing reverse transcriptase - polymerase chain response (RT-PCR) or genomic sequencing, to figure out whether the infection is "wild sort" (that is, the infection that causes polio sickness) or antibody sort (infection that could get from an immunization strain).

Serology

Serology might be useful in building up a conclusion of illness if acquired ahead of schedule throughout sickness. Two examples are required, one ahead of schedule in the [67,68] course of the disease and an additional three weeks after the fact. A four-fold ascend in the titer proposes poliovirus disease. Two examples in whom no counter acting agent is distinguished may preclude poliovirus contamination. There are restrictions to immune response titers. Patients who are immune-compromised may have two titers with no counter acting agent recognized and still be contaminated with poliovirus. For any patient, neutralizing [69] antibodies seem early and might be at abnormal states when the patient is hospitalized; in this way, a four-fold ascend in counter acting agent titer may not be illustrated. Somebody who has been inoculated and does not have poliovirus contamination may have an example with perceivable counter acting agent from the antibody.

Cerebrospinal Fluid (CSF)

In poliovirus disease, the CSF for the most part contains [70] an expanded number of white platelets (10–200 cells/mm³, principally lymphocytes) and a somewhat hoisted protein (40–50 mg/100 mL).

Prevention- starts correcting from here!

Oral polio vaccine (OPV)

The oral polio vaccine (OPV) was produced by Albert Sabin in 1961. Likewise called "trivalent oral polio antibody" or "Sabin vaccine", OPV comprises of a blend of live, lessened (debilitated) poliovirus [71] strains of every one of the three poliovirus sorts. OPV produces antibodies in the blood to each of the three sorts of poliovirus. In case of disease, these antibodies ensure against loss of motion by keeping the spread of wild poliovirus to the sensory system.

OPV additionally creates a nearby, mucosal resistant reaction in the mucous film of the guts. In case of disease, these mucosal antibodies restrict the replication [72] of the wild poliovirus inside the digestive tract. This intestinal insusceptible reaction to OPV is thought to be the primary motivation behind why mass battles with OPV can quickly stop individual to-individual transmission of wild poliovirus. The accompanying figure demonstrates polio antibody (Figure 1).

Manufacture

Oral polio vaccine (OPV) is an attenuated vaccine, created by the entry of the infection through non-human cells at a sub-physiological temperature, which produces unconstrained transformations in the viral genome. Oral polio antibodies were produced by a few gatherings, one of which was driven by Albert Sabin. Different gatherings drove by Hilary Koprowski and H.R. Cox, built up their own particular weakened antibody strains. In 1958, the National [73] Institutes of Health made an extraordinary board on live polio antibodies. The different antibodies were painstakingly assessed for their capacity to actuate insusceptibility to polio, while holding a low occurrence of neuropathogenicity in monkeys. Huge scale clinical trials performed in the Soviet Union in late 1950s to mid-1960s by Mikhail Chumakov and his associates showed wellbeing and high adequacy of the immunization. In view of these outcomes, the Sabin strains were decided for overall circulation. There are 57 nucleotide [74-76] substitutions which recognize the weakened Sabin 1 strain from its destructive guardian (the Mahoney serotype), two nucleotide substitutions constrict the Sabin 2 strain, and 10 substitutions are included in lessening the Sabin 3 strain. The essential constricting variable normal to every one of the three Sabin antibodies is a transformation situated in the infection's interior ribosome passage site (IRES) which changes stem-circle structures, and decreases the capacity of [77,78] poliovirus to decipher its RNA layout inside the host cell. The lessened poliovirus in the Sabin immunization imitates proficiently in the gut, the essential site of contamination and replication, however can't reproduce productively inside sensory system tissue. In 1961, sort 1 and 2 monovalent oral poliovirus immunization (MOPV) was authorized, and in 1962, sort 3 MOPV was authorized. In 1963, trivalent OPV (TOPV) was authorized, and turned into the antibody of decision in the United States and most different nations of the world, to a great extent supplanting the inactivated polio immunization.

OPV is typically given in [79] vials containing 10–20 measurements of immunization. A solitary dosage of oral polio antibody (typically two drops) contains 1,000,000 irresistible units of Sabin 1 (viable against PV1), 100,000 irresistible units of the Sabin 2 strain, and 600,000 irresistible units of Sabin 3. The immunization contains little hints of anti-microbial—neomycin and streptomycin—yet does not contain additives.

Advantages

OPV is managed orally. It can be given by volunteers and does not require prepared wellbeing specialists or sterile infusion equipment. The favorable position of this immunization is that it is moderately modest. In the year 2011, the cost of a solitary dosage for general wellbeing programs in creating nations was around 11 and 14 US pennies.

OPV is much protected, viable, and create or offer ascent to durable resistance against every one of the three sorts of poliovirus. After immunization for a few weeks, the infection present in the antibody [80] begin duplicating in the digestive tract, is discharged through dung, and can spread to others the individuals who are in close contact. This implies in ranges where cleanliness and sanitation are poor, consuming OPV can bring about passive immunization of individuals who have not been specifically vaccinated.

Disadvantages

In spite of the fact that OPV is sheltered and powerful, in [81] to a great degree uncommon cases (approx. 1 in each 2.7 million first measurements of the antibody) the live constricted immunization infection in OPV can bring about loss of motion. Sometimes it is trusted that this immunization related immobile polio (VAPP) might be activated by resistant lack.

The to a great degree generally safe of VAPP is outstanding and acknowledged by most general wellbeing programs on the planet on the grounds that without OPV, a huge number of youngsters would be disabled each year.

A second detriment is that infrequently the infection in the immunization may hereditarily change and begin to circle among a populace. These infections are known as coursing immunization inferred polioviruses (cVDPV).

Safety

OPV is a to a great degree safe [82] immunization. All OPV utilized as a part of supplementary vaccination exercises for the Global Polio Eradication Initiative is pre-qualified by WHO and obtained through UNICEF. In 2006, WHO issued an announcement to insist the quality and security of OPV.

Efficacy

OPV is exceptionally effective against every one of the three sorts of wild poliovirus. When this immunization is utilized be that as it may, there is rivalry among the [83] three infections to bring about immunity, which brings about assurance however not with equivalent productivity for every sort: it is best against sort 2. One measurements of OPV produces [84] invulnerability to each of the three poliovirus serotypes in around half of beneficiaries. Three measurements produce invulnerability in more than 95% of beneficiaries. Immunity is lifelong & most likely long lasting.

Recommended use

In many nations, OPV remains the antibody of decision in routine inoculation plans and supplementary vaccination exercises. Where more [84,85] than one sort of wild poliovirus is coursing, OPV is epidemiologically and operationally the best antibody to utilize in light of the fact that security creates to each of the three sorts of polio infection.

Inactivated polio vaccine (IPV)

Inactivated polio immunization (IPV) was created in 1955 by Dr. Jonas Salk. Likewise called the "Salk antibody", IPV comprises of inactivated (murdered) poliovirus strains of every one of the three poliovirus sorts. IPV is given [86] by intramuscular infusion and should be directed by a prepared wellbeing laborer. The inactivated polio immunization produces antibodies in the blood to every one of the three sorts of poliovirus. In case of disease, these antibodies keep the spread of the infection to the focal sensory system and secure against loss of motion. IPV is [87] infused in the leg or arm, contingent upon age. IPV is given to a youngster at age of 2, 4 and 6-year and a half. A promoter measurement is required at 4-6 years.

Grown-ups usually [88-90] needn't bother with polio immunization on the off chance that they have been inoculated as kids. In any case, the individuals who are venturing out to a spot where there is a polio flare-up, those working with tests of polio infection in a research center and those living in contact with a polio infection contaminated individual may should be immunized.

Pregnant women, those with a stifled immunity [91] and those with HIV require to be inoculated with IPV. Grown-up regimen of immunization is first measurement whenever took after by second dosage 1 to 2 months after the fact and third measurement 6 to 12 months after the second.

Manufacture

The Salk immunization, or inactivated poliovirus antibody (IPV), depends on three wild, destructive reference strains, Mahoney (sort 1 poliovirus), MEF-1 (sort 2 poliovirus), and Saukett (sort 3 poliovirus), developed in [91,92] a kind of monkey kidney tissue society (Vero cell line), which are then inactivated with formalin [93]. The infused Salk antibody gives IgG-interceded insusceptibility in the circulatory system, which keeps polio disease from advancing to viremia and ensures the engine neurons, consequently taking out the danger of bulbar polio and post-polio disorder.

Advantages

As IPV is not a "live" antibody, it conveys no danger of immunization related polio loss of motion.

IPV triggers an excellent defensive immune reaction in many people.

Disadvantages

IPV instigates low levels of resistance in the digestive system. Therefore, when a man vaccinated with IPV is contaminated with wild [94] poliovirus, the infection can in any case increase inside the digestion systems and be shed in the dung, gambling proceeded with flow.

IPV is more than five times more costly than oral polio immunization.

Overseeing the immunization requires prepared wellbeing specialists and sterile infusion gear and methodology.

Safety

IPV instigates low levels of resistance in the digestive system. Therefore, when a man vaccinated with IPV is contaminated with wild [94] poliovirus, the infection can in any case increase inside the digestion systems and be shed in the dung, gambling proceeded with flow.

IPV is more than five times more costly than oral polio immunization.

Overseeing the immunization requires prepared wellbeing specialists and sterile infusion gear and methodology.

Safety

IPV is one of the most secure antibodies being used. No genuine systemic unfriendly responses have been appeared to take after immunization.

Efficacy

IPV is very powerful in anticipating immobile sickness brought on by every one of the three sorts of poliovirus.

Recommended use

An increasing number [95] of industrialized, polio-free countries are using IPV as the vaccine of choice. This is because the risk of paralytic polio associated with continued routine use of oral polio vaccine (OPV) is deemed greater than the risk of imported wild virus.

However, as IPV does [96] not stop transmission of the virus, oral polio vaccine is used wherever a polio outbreak needs to be contained, even in countries which rely exclusively on IPV for their routine immunization programme (e.g. the polio outbreak in the Netherlands in 1992).

IPV is not recommended [97] for routine use in polio-endemic countries or in developing countries at risk of poliovirus importations. In these countries, oral polio vaccines – trivalent, bivalent or monovalent, depending on local epidemiology – are used.

Once polio has been eradicated, use of the oral polio vaccine will need to be stopped to prevent re-establishment of transmission due to vaccine-derived polioviruses. Switching to IPV is one option for this post-OPV era.

Treatment

There is no cure for polio. The center of current treatment [98] has been on giving alleviation of side effects, speeding recuperation and forestalling inconveniences. Steady measures incorporate anti-toxins to anticipate diseases in debilitated muscles, analgesics for agony, moderate activity and a nutritious diet [99]. Treatment of polio regularly requires long haul restoration, including word related treatment, non-intrusive treatment, props, remedial shoes and, now and again, orthopedic surgery.

Versatile ventilators might be required to bolster relaxing. Truly, a noninvasive, antagonistic weight ventilator, all the more usually called an iron lung, was utilized to misleadingly keep up breath amid [100] an intense polio contamination until a man could inhale freely (by and large around one to two weeks). Today, numerous polio survivors with changeless respiratory loss of motion use present day coat sort negative-weight ventilators worn over the mid-section and mid-region.

Other chronicled medications for polio incorporate hydrotherapy, electrotherapy, back rub and aloof movement works out, and surgical medicines, for example, ligament protracting and nerve joining.

Conclusion

Polio is a conundrum. It is an illness that was, in every way that really matters, ceased in the twentieth century. It is likewise, to some degree, a result of the twentieth century. The infection was constantly here, yet it was current innovation—present day techniques for sanitation—that transformed the endemic into the plague. It is a clear update that we are not honored with 20/20 prescience. Who could have anticipated, toward the end of the nineteenth century, that the moves we made to shield our populace from certain fear maladies would discharge a considerably more fear sickness upon us.

In spite of the fact that we now and then wish for simply this kind of insightful learning, maybe we are in an ideal situation without it. Had we seen the aftereffects of our activities, would we have exchanged typhoid and cholera for polio? Keep in mind that in its most exceedingly terrible year, polio tainted fewer than 30,000 individuals across the nation. To differentiate, 90,000 individuals passed on in Chicago alone in the 1885 typhoid/cholera pestilence. That our activities have unanticipated and unforeseeable outcomes are something to recall as we attempt to plot our way into what's to come. What may we have done in the 70s to mollify pressure and reduce starvation in Africa had we realized that the subsequent convergence of individuals into the urban areas would have an immediate result on the spread of some time ago uncommon infection that we now call HIV?

It is presently associated that some with the antibody that was utilized as a part of the first polio trials and inoculations were developed from the kidneys of monkeys contaminated with something many refer to as Simian Virus 40. SV40 is associated with bringing about some uncommon types of growth.

References

1. Najam R, et al.A Large Fibroma Polyp of Labia Majora–A Case Report. J Clin Case Rep. 2013;3:297.
2. Kumar SB andGautam S. Improvement in Sperm DNA Quality Following Simple Life Style Intervention: A Study in Fathers of Children with Non-Familial Sporadic Heritable Retinoblastoma. J Clin Case Rep.2015;5:509.
3. McMicken BL and Kunihiro A. Language Remediation in a Case of Wernicke’s Aphasia Post Herpes Simplex Virus Type 1 Viral Encephalitis. J Clin Case Rep. 2014;4:441.
4. Giri P and Shukla R.Paraneoplastic Cerebellar Degeneration: A Rare but Important Consideration. J Clin Case Rep. 2016;6:700.
5. Alkuraishy H andAlgareeb A. Modulation effects of Piracetam and Ginkgo Biloba on the Cognitive and Working Memory Functions: Psychometric Study. J NeurolNeurophysiol. 2014;5:234.
6. Menezes KK. Physical Therapy Rehabilitation after Traumatic Brain Injury. J NeurolNeurophysiol.2015;6:311.
7. Moretti DV, et al.Temporo-Parietal Brain Network Impairment Is Related to EEG ALPHA3/ALPHA2 Power Ration in ProdormalAlzheimer ’s disease. J NeurolNeurophysiol. 2013;4:160.
8. Parakh Mand Katewa V.A Review of the Not So Benign- Benign Childhood Epilepsy with Centrotemporal Spikes. J NeurolNeurophysiol. 2015;6:314.
9. Delacroix S, et al. Hypertension: Pathophysiology and Treatment. J NeurolNeurophysiol. 2014;5:250.
10. Kumada T, et al. Modified Atkins Diet and Low Glycemic Index Treatment for Medication-Resistant Epilepsy: Current Trends in Ketogenic Diet. J NeurolNeurophysiol. 2013.
11. Khalil S, et al. Postoperative Cognitive Dysfunction: An Updated Review. J NeurolNeurophysiol. 2015;6:290.
12. Brotis AG. Hemispherectomy: Indications, Surgical Techniques, Complications, and Outcome. J NeurolNeurophysiol. 2015;6:300.
13. Mou X. Hippocampal CA2 Region: A New Player in Social Dysfunctions. J NeurolNeurophysiol. 2016;7:357.
14. Weidner BA, et al. Adult Night Terrors Since Childhood: A Case Report. J NeurolNeurophysiol. 2016;7:346.
15. Newey CR andSarwal A.Hyponatremia and Voltage Gated Potassium Channel Antibody Associated Limbic Encephalitis. J NeurolNeurophysiol. 2014; 5:195.
16. Wyck DWV, et al. Penetrating Traumatic Brain Injury: A Review of Current Evaluation and Management Concepts. J NeurolNeurophysiol. 2015;6:336.
17. Bernardo CD, et al. Myasthenia Gravis and Its Comorbidities. J NeurolNeurophysiol. 2015;6:317.
18. Ferdinand P andOke A. Intractable Hiccups Post Stroke: Case Report and Review of the Literature. J NeurolNeurophysiol. 2012;3:140.
19. Mainardi P, et al. From the Ancient Diets to the Recent Acquisitions on the Role of Brain Inflammation in Epilepsy, Are there Any Links?. J NeurolNeurophysiol. 2015;6:304.
20. Piemonte MEP, et al. Extensive Training Promotes Performance Improvement but not Automaticity in Patients with Parkinson’s disease. J NeurolNeurophysiol. 2015;6:324.
21. Shah J, et al. Varicella-Zoster Virus Vasculopathy: A Case Report Demonstrating Vasculitis using Black-Blood MRI. J NeurolNeurophysiol. 2015;6:342.
22. Shah J, et al. Virus Vasculopathy: A Case Report Demonstrating Vasculitis using Black-Blood MRI . J NeurolNeurophysiol. 2015;6:342.
23. Hu W andLuo JJ. Research Advances in Pick’s Disease: A New Biomarker Candidate. J NeurolNeurophysiol. 2013; 4:112.
24. Fraioli MF, et al. Trigeminal Neuralgia: Role and Neurosurgical Indications of Peripheral Alcohol Injections Controlled Radiofrequency Thermocoagulation, Gasserian Ganglion Compression with Balloon and Microvascular Decompression in Posterior Cranial Fossa. Experience in 437 Patients. J NeurolNeurophysiol. 2011;2:109.
25. Borzillo V, et al. Radiosurgery and Stereotactic Radiotherapy for Brain Metastases According the New Prognostic Indexes: our Preliminary Experience. J NeurolNeurophysiol. 2015;6:340.
26. Abdulhafeez MK, et al. EEG Profile & Yield in Evaluation of First Non-febrile Seizures in Children-First Observational Study in Qatar. J NeurolNeurophysiol. 2015;6:330.
27. Nayyar AS, et al. Gingival Enlargement in Epileptic Patients on Phenytoin Therapy-An Evidence Based Approach. J NeurolNeurophysiol. 2012;3:127.
28. Herbowski LandGurgul H. The Structure of the Electric Double Layer of Macromolecules Suspended in Human Cerebrospinal Fluid. J NeurolNeurophysiol. 2011;2:108.
29. Saeed S, et al. The Use of Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis: An Overview of Open Labels and Ongoing Studies. J NeurolNeurophysiol. 2014;5:219
30. Campos LMG, et al. Neuroanatomical Mapping of s100 Immunoreactivity Reviewed. J NeurolNeurophysiol. 2015;6:326.
31. Dababneh H, et al. Observation of Mean Transit Time (Mtt) Perfusion Maps on a 320-Detector Row Ct Scanner and its Potential Application in Acute Ischemic Stroke. J NeurolNeurophysiol. 2011;2:117.
32. Galeote A, et al. Neurological Rehabilitation after Severe Traumatic Brain Injury, New Tools New Hopes: The Hippo Therapy Approach. J NeurolNeurophysiol. 2014;5:231.
33. Tabaac BJ, et al.Incidentaloma: The Case of an Asymptomatic MediastinalGanglioma. J NeurolNeurophysiol. 2016;7:347.
34. Kikuchi K, et al. Beneficial Effects of the Free Radical Scavenger Edaravone (Radicut) in Neurologic Diseases. J NeurolNeurophysiol. 2011;S1.
35. Hölscher T, et al. Noninvasive Transcranial Clot Lysis Using High Intensity Focused Ultrasound. J NeurolNeurophysiol. 2011;S1.
36. Syndi SDOandPellock JM.Recent Research on Febrile Seizures: A Review. J NeurolNeurophysiol. 2013;4:165.
37. Kar SK,et al. The Analgesic Efficacy of Preoperative Lornoxicam in Prevention of Postoperative Pain after Septoplasty. J NeurolNeurophysiol. 2016;7:353.
38. Salih MA, et al. Ocular Neostigmine Drops for Diagnosing Myasthenia Gravis. J NeurolNeurophysiol. 2013;11:004.
39. Totaro R, et al. Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting. J NeurolNeurophysiol. 2015;6:337.
40. Altunel A, et al. The Utility of the Hypsarrhythmia Paroxysm Index and Sleep Spindles in EEG for Predicting Cognitive Outcomes in a Case Series of Infantile Spasms. J NeurolNeurophysiol.2015;6:319.
41. Araki Aand Ito H. Psychological Risk Factors for the Development of Stroke in the Elderly. J NeurolNeurophysiol. 2013;4:147.
42. Monteiro CES, et al. Prevention and Reversal of Morphine-Induced Tolerance by Novel Muscarinic Receptor Agonist in Rats with Neuropathic Pain. J NeurolNeurophysiol. 2015;6:282.
43. Suski Jand Goldman M. Demyelinating Lesion Isolated to the Lateral Geniculate Nucleus. J NeurolNeurophysiol. 2014;12:12-14.
44. Ohki M. Sensorineural Hearing Loss Due to Vertebrobasilar Artery Ischemia–Illustrative Case and Literature Review. J NeurolNeurophysiol. 2013;8:005.
45. Nimjee SM, et al. Endovascular Intracranial Micro-Catheter Placement to Treat Cavernous Sinus Thrombosis. J NeurolNeurophysiol. 2015;6:309.
46. Cherchi M, et al. Amplitude of Sound Evoked Triceps Myogenic Potential Scales with Force. J NeurolNeurophysiol. 2015;6:286.
47. Ali BM, et al. Bilateral Vocal Cord Dysfunction in the Setting of Lateral Medullary Infarction: A Case Report and Review of Neuro-Anatomical Correlate. J NeurolNeurophysiol. 2015;6:333.
48. Bryan YG. Traumatic Brain Injury. J NeurolNeurophysiol. 2013;4:174.
49. Nathalie E, et al. Short-Term Memory Impairment Sparing the Central Executive in Relapsing-Remitting Multiple Sclerosis. J NeurolNeurophysiol.2014;5:202.
50. LuoJ. A Practical Approach to Neurophysiologic Intraoperative Monitoring. J NeurolNeurophysiol. 2015; 6:266.
51. Pavlova MK, et al. Unexpected EEG Abnormalities in Adults with Parasomnia – A Case Series. J NeurolNeurophysiol. 2014;5:246.
52. Cintra MTG, et al. P300 Evoked Potential and Risk of Mild Cognitive Impairment Progression to Alzheimer’s Dementia: A Literature Review. J NeurolNeurophysiol. 2015;6:322.
53. William YJ. Neurological Implications in the Treatment of Myopia by Means of Orthoculogy. J NeurolNeurophysiol. 2014;5:257.
54. Phillip D, et al. Spontaneous Low Frequency Oscillations in Acute Ischemic Stroke –A Near Infrared Spectroscopy (NIRS) Study. J NeurolNeurophysiol. 2014;5:241.
55. Dziadkowiak E, et al. Composed Paraneoplastic Neurological Syndrome, Disseminated in Time and Space, in the Course of Non-Small Cell Neuro-Endocrine Lung Cancer. J NeurolNeurosci. 2016;7:S3.
56. White LD, et al. Adult Onset Acute Disseminated Encephalomyelitis Following Appendicitis: A Case Report. J NeurolNeurosci. 2016;7:3.
57. Oliveira CR, et al. Use of Bells Test in the Evaluation of the Hemineglect Post Unilateral Stroke. J NeurolNeurosci. 2016;7:3.
58. Shilpa R, et al. Association of Genetic Markers Contributing to Dyslexia Susceptibility in Indian Population. J NeurolNeurosci. 2016;7.
59. Mamum AA, et al. Neurodefensive Effect of Oleaeuropaea L. in Alloxan-Induced Cognitive Dysfunction and Brain Tissue Oxidative Stress in Mice: Incredible Natural Nootropic. J NeurolNeurosci. 2016;7:3.
60. Salem TB, et al. Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus. J NeurolNeurosci. 2016;7:3.
61. Rodriguez SM. Brain Connectivity as Potential Biomarker for Alzheimer's Disease. J NeurolNeurosci. 2016;7:3.
62. Castelli I, et al. Theory of Mind in Unsuccessful Neurocognitive Aging: Preliminary Evidence from an aMCI-Converter to AD and from an aMCIReverter to Near-Normal Cognition. J NeurolNeurosci. 2016;7:3.
63. Endo T, et al. Impact of Extraischemic Hemorrhage after Thrombolysis with Intravenous Recombinant Tissue Plasminogen Activator. J NeurolNeurosci. 2016;7:3.
64. Thompson SBN. Communicating with the Motor Cortex? Cortisol and Yawning as Possible Biomarkers for the Detection of Neurological Disease. J NeurolNeurosci. 2016;7:3.
65. Fraioli MF, et al. Spinal Liquoral Metastasis from Cerebral Anaplastic Oligodendroglioma: Case Report. J NeurolNeurosci. 2016;7:3.
66. Cuoco JA, et al. Hypothetical Link between Osteopathic Suboccipital Decompression and Neuroimmunomodulation. J NeurolNeurosci. 2016;7:3.
67. Muller M, et al. Width of The Third Ventricle as Assessed by TranscranialSonography is associated with Future Relapses in Mild Multiple Sclerosis. J NeurolNeurosci. (2016);7:3.
68. Finkelstein Y, et al. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res Rev 1998;27:168-176.
69. Jack CRJ, et al. Age, sex and APOE epsilon4 effects on memory, brain structure and beta-amyloid across the adult life span. JAMA Neurol.2015;72:511-519.
70. Bennett DA, et al. Cognitive and social life-style: links with neuropathology in late life. ActaNeuropathol. 2014;127:137-50.
71. Negash S, et al. Cognition and neuropathology in aging: multidimensional perspective from the Rush Religious Orders Study and Rush Memory Aging Project. Curr Alzheimer Res.2011;8:336-340.
72. Hackett PH, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA. 1998;280:19-20.
73. FandiñoFJ. Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. J NeurolDisord. 2015;3:115.
74. Stanton AA. Functional Prodrome in Migraines. J NeurolDisord. 2016;4:256.
75. Ardila A. There are Two Different Dysexecutive Syndromes. J NeurolDisord. 2013;1:114.
76. Pritchard C and Silk A. A Case-Study Survey of Eight-year Cluster of Motor Neurone Disease (MND) Referrals in a Rural English Village: Exploring Possible Aetiological Influences in a Hypothesis Stimulating Study. J NeurolDisord. 2014;2:147.
77. Doherty GH.Homocysteine and Parkinson’s Disease: A Complex Relationship. J NeurolDisord. 2013;1:107.
78. Oliveira T, et al. Incidence of Epilepsy in Adults with Cerebral Palsy and Secondary Health Outcomes: A Review and Proposed Feasibility Study. J NeurolDisord. 2014;2:188.
79. Maner F, et al. The Coexistence of Arachnoid Cyst with First Episode Psychosis: Four Cases. J NeurolDisord. 2014;2:186.
80. Divyakolu S, et al. Evaluation of C677T Polymorphism of the MethylenetetrahydrofolateReductase (MTHFR) Gene in various Neurological Disorders. J NeurolDisord. 2013;2:142.
81. Medeiros FC, et al. Thoracic Spinal Cord Atrophy Due to Vitamin B12 Deficiency. J NeurolDisord. 2014;2:101.
82. Escuti N. Headache in a Patient with an ExtracranialLipoma: Report of a New Case. J NeurolDisord. 2015;3:250.
83. Jung H, et al. Perioperative Cerebrospinal Fluid Diversion Utilizing Lumbar Drains in Transsphenoidal Surgery. J NeurolDisord. 2014;2:150.
84. Pearce JMS. The Neurology of Erasistratus. J NeurolDisord. 2013;1:111
85. Mizuno T. Auditory Hallucinations and Its Mechanism. J NeurolDisord. 2015;3:230.
86. Noda M, et al. Multiple Effects of Molecular Hydrogen and its Distinct Mechanism. J NeurolDisord.2014;2:189.
87. Edahiro S, et al. Spectral Analyses of Heart Rate Variability by Acceleration Plethysmography for Diagnostic Support of Migraine: Clinical Research. J NeurolDisord. 2015;3:229.
88. Lelieveld IM, et al. Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease. PLoS One. 2015;10:0137603.
89. Ramberger M, et al. NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases. NeurolNeuroimmunolNeuroinflamm. 2015;2:141.
90. Hawthorne C and Piper I. Monitoring of Intracranial Pressure in Patients with Traumatic Brain Injury. Front Neurology 2014;5.
91. Dias JC, et al. Inflammatory Polyneuropathy after Bariatric Surgery: Report of Two Cases. J NeurolDisord. 2016;4:278.
92. Tiwari A, et al. Role of Platelets in Glutamate Mediated Excitotoxicity: An Overview. J NeurolNeurophysiol. 2015;6:312.
93. Fallatah S. Neurologic Complications after Spinal Surgery: Personal Experience. J NeurolDisord. 2015;3:216.
94. Ahmed WAM, et al. Health Education Module for Stroke Caregivers. J NeurolDisord. 2015;3:211.
95. Teche SP, et al.Dacrystic Seizures and Psychogenic Non-Epileptic Seizures: A Case Report. J NeurolDisord. 2015;3:249.
96. Novak P. Quantitative Scale for Grading of Cardiovascular Autonomic Reflex Tests and Small Fibers from Skin Biopsies (QASAT). J NeurolDisord. 2015;3:226.
97. Jahanbazi A, et al. Effects of EMG Biofeedback on Pain and Quality of Life in Cervical Dystonia. J NeurolDisord. 2013;2:144.
98. Aydin HE, et al. Use of Dural Graft to Prevent Cerebrospinal Fluid (CSF) Leakage and its Effects on Medulla Spinalis: An Experimental Study. J NeurolDisord. 2015;3:202.
99. Herath P, et al. Status Dystonicus: A Rare, but a Serious Movement Disorders Emergency. J NeurolDisord. 2014;2:193.
100. Maslehaty H, et al. Treatment of Intraventricular Hemorrhage (IVH) by Injection of Recombinant Tissue-type Plasminogen Activator (rtPA)–Single Institution Experiences with 80 Patients. J NeurolDisord. 2013;1:113.